Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

# Background Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2013-06-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9854
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items